Kezar Life Sciences, Inc.

This study tested a new drug called zetomipzomib in 24 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. Participants received either the drug or a placebo along with their usual treatment for 24 weeks, with an option to continue the drug fo…

This study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616…

This study tested a new drug called KZR-616 (zetomipzomib) in 69 people with lupus, some of whom also had kidney inflammation (lupus nephritis). Participants received weekly injections for 13 or 24 weeks. The main goals were to check safety and see if the drug could reduce protei…

This Phase 2 trial tested a drug called KZR-616 (zetomipzomib) in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received either the drug or a placebo for 16 weeks, then switched to the other trea…